Search research articles
Contact Us
Filters
Showing results (111-120 of 182) with videos related to
Page
of 19
Sort By:
Cancer Cell
|
February 16, 2005
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
M Golam Mohi, Ifor R Williams, Charles R Dearolf, et al.
Blood
|
June 29, 2006
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
Thomas Mercher, Gerlinde Wernig, Sandra A Moore, et al.
Cancer Cell
|
September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway
Sumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
Blood
|
December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
Jeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Blood
|
July 21, 2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo
Elizabeth H Stover, Jing Chen, Benjamin H Lee, et al.
Oncogene
|
August 24, 2005
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model
Benjamin H Lee, Ifor R Williams, Ema Anastasiadou, et al.
Immunity
|
April 13, 2022
The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade
Lisa Cucolo, Qingzhou Chen, Jingya Qiu, et al.
Blood
|
August 30, 2011
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome
Madhu S Kumar, Anupama Narla, Atsushi Nonami, et al.
Molecular Cancer Therapeutics
|
May 24, 2013
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
Amy D Guertin, Jing Li, Yaping Liu, et al.
Cancer Cell
|
October 16, 2007
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
Benjamin H Lee, Zuzana Tothova, Ross L Levine, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 182) with videos related to
Sort By:
Page
of 19
Cancer Cell
|
February 16, 2005
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
M Golam Mohi, Ifor R Williams, Charles R Dearolf, et al.
Blood
|
June 29, 2006
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
Thomas Mercher, Gerlinde Wernig, Sandra A Moore, et al.
Cancer Cell
|
September 6, 2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway
Sumin Kang, Shaozhong Dong, Ting-Lei Gu, et al.
Blood
|
December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients
Jeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Blood
|
July 21, 2005
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo
Elizabeth H Stover, Jing Chen, Benjamin H Lee, et al.
Oncogene
|
August 24, 2005
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model
Benjamin H Lee, Ifor R Williams, Ema Anastasiadou, et al.
Immunity
|
April 13, 2022
The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade
Lisa Cucolo, Qingzhou Chen, Jingya Qiu, et al.
Blood
|
August 30, 2011
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome
Madhu S Kumar, Anupama Narla, Atsushi Nonami, et al.
Molecular Cancer Therapeutics
|
May 24, 2013
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
Amy D Guertin, Jing Li, Yaping Liu, et al.
Cancer Cell
|
October 16, 2007
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia
Benjamin H Lee, Zuzana Tothova, Ross L Levine, et al.
Page
of 19